Trinity Biotech plc (TRIB) Deserves To Be On Your Radar Today

Trinity Biotech plc (NASDAQ:TRIB) is one of the stocks that are taking the center stage today as the company shares are trading 6.34% or 0.077 points higher from last closing price of $1.22, reaching $1.2974 at last check. So what’s going on with TRIB shares anyway? The price has risen in 1 of the last 5 days and is down -31.07% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 286,220 shares, and in total 348320 shares valued at $451910 were seen changing hands compared with 62100 shares valued at $75762 recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the TRIB stock.

Trinity Biotech plc (TRIB) shares have notched a 3-month decline of about -31.07%, but has still tumbled -46.72% year to date. By comparison, the stock sank -67.81% over the past 12 months, while it slipped -31.84% over the 1 month. The company’s market cap is around $29.1M, with its short interest ratio standing at 5.07%.

In the current trading session for TRIB, the stock witnessed two major price actions, it rose to a high of $1.3009 and was down as much as $1.1859 at one point. The high recorded is very low when compared to their 52-week high which is $1.21. The 52-week high is now at -70.71 distance from current price. Their recent low of $4.37 represents a 5.79% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for TRIB is $6, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Trinity Biotech plc earned $-1.41 per share in the trailing 12 months and has a P/E ratio of -0.92. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 38 and lower compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. TRIB also has P/S multiple of 0.33. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 0.79x.

TRIB‘s last price was down -46.16% as compared to the average trading price of 50 days recorded at $2.41 while enlarging the period to 200 trading days, the average closing price was $1.86. At present, there are 23.85 million in the total number of common shares owned by the public and among those 18.99 million shares have been available to trade. The percentage of shares being held by the company management was 11.2% while institutions stake was 49.3%. The company has generated negative returns on equity over the last 12 months (-58.7%). It managed to keep its gross profit margin at 42% over the past 12 months.

When assessing the full upside of the TRIB stock, there is another set of technicals that should be looked into and considered. Its -8.83% decline from moving average of $1.42 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.5 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

In the last five years, the EPS of the company has been roughly -35.9%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 15%. The revenue of the company has risen at an average annualized rate of about 1.2 over the last five years. The company recently recorded a drop of -10%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards TRIB stock. White Pine Capital LLC trimmed position in the company after it dumped -31.3% or 80,844 shares of its common stock. The hedge fund now owns 55,540 shares worth $72,058, SEC documents show. First Wilshire Securities Management Inc. cut assets in the stock as 981716.9 shares have been sold, reducing its stake by -19.1% to 794,209 shares which are currently valued at $1,030,407. In addition, Renaissance Technologies LLC recently reported that it now owns 685,496 shares making a total of $889,363 based on the recent price. This refelects a change of 11.7% in their ownership.